Larazotide, he waha liilii, peptide synthetic a me kahi antagonist koho o zonulin He ʻokoʻa ia mai nā lāʻau lapaʻau ʻē aʻe no ka mea ʻaʻole hoʻopaʻa kēia pūhui i kekahi mea loaʻa.
He hana ma kahi adjuvant kuleana (i loaʻa mai ka palapala a me ke kamaʻilio pilikino) ma ka hoʻomaʻamaʻa ʻana i kahi pale ʻōpū dysfunctional i ʻike ʻia ma ka liʻiliʻi ma maʻi celiac.
Kāohi ʻo Larazotide i ka wehe ʻana o ka hui ʻana i ka gluten-mediated a he lāʻau lapaʻau maikaʻi ʻole no ka poʻe maʻi CD ma lalo o a. GFD.
Ua hōʻike ʻo Larazotide i ka maikaʻi hoʻohiki i ka hoʻomohala ʻana i ka lāʻau lapaʻau ma nā haʻawina Phase IIb, ʻoi loa no nā hōʻailona mau.
Ma waho aʻe o kāna noi mua i nā maʻi gastrointestinal, Ua hōʻike mua nā haʻawina in vitro i ka hana antiviral o Larazotide ka maʻi varicella-zoster (VZV), e alakaʻi ana i nā noi hou i nā maʻi maʻi.
Ma ke kahua o nā lāʻau lapaʻau, ʻO Larazotide kahi hoʻokō therapeutic peptide waha nui.
Ua hōʻike ʻia ka ʻilihune waha o nā lāʻau peptide maʻamau no ka mea ua hoʻohaʻahaʻa ʻia lākou e nā enzyme GI..
Hāʻawi kēia ʻano hana hou iā ia e hana i nā pahuhopu o ka ʻōpū ma ka ʻāina me ka liʻiliʻi o ka ʻōnaehana systemic absorption, e hōʻemi ana i nā hopena ʻaoʻao systemic.
Kaʻina
H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH
Helu CAS
258818-34-7
ʻĀpana Molekala
C32H55N9O10
Kaumaha Molekala
725.83
Noiʻi o Larazotide
1.Hoʻomaopopo i ka pahuhopu a me ka hoʻolālā lāʻau
Zonulin, ka protein e hoʻoponopono ai ʻōpū liʻiliʻi (A ME) paracellular permeability i loko o ka reversible a hiki ole Ua ʻike ʻia ke ʻano.
ʻOiai inā ʻo ka ʻano hana o Larazotide ua like ia me kela AT-1001–ʻo ia hoʻi, kahi paʻa o ka zonulin i hoʻopaʻa ʻia i kona mea loaʻa a ma o kēia pale ʻana i ka piʻi ʻana o ka ʻōpū o ka ʻōpū ma o ka attenuation o zonulin mai nā hui paʻa-, ua hoʻāʻo ʻia ʻo ia ka modulator TJ mua i nā kānaka.
Eia naʻe, ma muli o kona kaʻina waika amino ʻokoʻa a me ka hoʻokumu ʻana i ka paʻakai acetate (Larazotide acetate, CAS No 881851-50-9), Larazotide [Ac-KPFSLSQ(Cys)] hōʻike i ke kūpaʻa kiʻekiʻe a me ka bioavailability kūloko i loko o ka ʻōpū.
2.Hoʻololi ʻia o ka hana ʻāʻī o ka ʻōpū
Loaʻa ʻo Larazotide i ka waiwai ʻepekema hohonu ma ke ʻano he ala hou a ikaika hoʻi i ka modulation kikoʻī o ka hana pale ʻōpū..
Hoʻohana nui ʻia kāna hana ma o ka hoʻohālikelike ʻana o zonulin, e hoʻokūkū ana me zonulin no ka hoʻopaʻa ʻana i nā mea loaʻa ma ka ʻili luminal o enterocytes.
ʻO kēia ke alakaʻi ʻana i ka inhibition o intracellular activation o myosin light-chain kinase (MLCK), ʻO ka hoʻonohonoho hou ʻana o ka cytoskeletal a me ka wehe ʻana o nā protein hui paʻa SE-1.
Ma kēia ʻano molekala Larazotide e hoʻopaʻa i ka paʻa o nā hui paʻa a keʻakeʻa i ka unuhi makemake ʻole ʻia. macromolecules e.g., gliadin.
3.Ka mālama ʻana i ka maʻi Celiac
ʻO ka maʻi Celiac (CD) he autoimmune enteropathy, hoʻomaka ʻia e ka ʻike ʻana i ka gluten in genetically predisposed poʻe, a pili e pili ana 1% o ka heluna kanaka o ka honua.
I kēia manawa, ʻO ka mālama ʻana i ka meaʻai gluten-free ka lāʻau lapaʻau i hōʻoia ʻia.
Eia naʻe, paʻakikī ka mālama lōʻihi i ka meaʻai; He paʻakikī paha ka pale ʻana i ka launa ʻana a ke hoʻomau nei nā hōʻailona i nā maʻi he nui.
Ma kona kumu, ʻO ka MOA o Larazotide i loko o ka maʻi celiac ka mea koho koho i ka wehe ʻana o TJ i hoʻokomo ʻia e zonulin.
I ka maʻi celiac, i ka pane ʻana i ka deamidated gliadin peptides, enterocyte CXCR3 Hoʻokomo ʻia ka hoʻokuʻu ʻana o zonulin.
Hoʻopili ka zonulin manuahi me kona loaʻa ma ka papa epithelial, ka hoʻoulu ʻana i nā ala hōʻailona intracellular e alakaʻi i ka myosin light-chain phosphorylation.
ʻO kēia ka hopena i ka relocalization o nā protein hui paʻa (e like me ZO-1, occludin a claudins) a cytoskeleton ka hoʻonohonoho hou ʻana me ka hoʻonui ʻana i ka permeability o ka ʻōpū.
ʻO Larazotide kahi mea hoʻokūkū octapeptide-antagonist, hoʻopaʻapaʻa hoʻokūkū a hoʻohuli ʻia i nā mea loaʻa zonulin ma ka ʻili luminal o nā cell epithelial, e ālai ana i kēia kaʻina hana hōʻailona cascade, a mālama i ka homeostasis pale.
Hoʻokomo ʻia kahi hoʻokolohua lapaʻau Phase IIb 342 nā maʻi me nā hōʻailona hoʻomau i ka hoʻonohonoho ʻana o kahi GFD.
ʻO kahi maʻi o 0.5 Ua hōʻike ʻia ka mg ʻekolu manawa i kēlā me kēia lā i ka maikaʻi a ʻoi aku ka maikaʻi ma mua o ka placebo ma ke ʻano o ka hōʻemi ʻana i nā hōʻailona o ka maʻi gastrointestinal me kahi ʻike palekana a me ka hoʻomanawanui ma mua o ke aʻo hou ʻana..
4.Mea Antiviral
Ma waho aʻe o kāna hoʻohana ʻana i ka ʻōpū ʻāʻā, Ua hōʻailona ʻo Larazotide i ka pono antiviral in vitro e kūʻē iā VZV.
Hoʻonui kēia ʻike i kona hiki ke hoʻōla a hōʻike i nā ʻano hana like ʻole hiki ke hana.
Hōʻike ka hōʻike in vitro ʻo Larazotide ke kāohi i ka hana hou ʻana o VZV OKA a 07-1 ke kaumaha me EC₅₀ o 44.14 μM a 59.06 μM, pakahi.
He haʻahaʻa kēia pae o ka hana no kahi lāʻau antiviral.
Eia naʻe, e like me ka hana o Larazotide i localized me ka 'ano nui puka makani lapaʻau, hoʻohui kēia i ka waiwai nui i ka hoʻomohala ʻana i ke kino.
ʻIke ʻia, ka cytotoxicity o kēia mea hana i loko o nā pūnaewele hoʻokipa (Nā pūnaewele Vero) hōʻike ʻia a CC₅₀ waiwai o 82.5 μM, e hāʻawi ana i kahi lākiō TI o ~1.4-1.9.
Hōʻike kēia i kahi mea palekana haʻahaʻa akā hiki ke ʻae ʻia i nā ʻano antiviral i kūpono.
COA
HPLC
MS





